Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Acta Pharmacol Sin ; 45(6): 1160-1174, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38438581

ABSTRACT

Nicotinic acetylcholine receptors (nAChRs) regulate pain pathways with various outcomes depending on receptor subtypes, neuron types, and locations. But it remains unknown whether α4ß2 nAChRs abundantly expressed in the substantia nigra pars reticulata (SNr) have potential to mitigate hyperalgesia in pain states. We observed that injection of nAChR antagonists into the SNr reduced pain thresholds in naïve mice, whereas injection of nAChR agonists into the SNr relieved hyperalgesia in mice, subjected to capsaicin injection into the lower hind leg, spinal nerve injury, chronic constriction injury, or chronic nicotine exposure. The analgesic effects of nAChR agonists were mimicked by optogenetic stimulation of cholinergic inputs from the pedunculopontine nucleus (PPN) to the SNr, but attenuated upon downregulation of α4 nAChRs on SNr GABAergic neurons and injection of dihydro-ß-erythroidine into the SNr. Chronic nicotine-induced hyperalgesia depended on α4 nAChRs in SNr GABAergic neurons and was associated with the reduction of ACh release in the SNr. Either activation of α4 nAChRs in the SNr or optogenetic stimulation of the PPN-SNr cholinergic projection mitigated chronic nicotine-induced hyperalgesia. Interestingly, mechanical stimulation-induced ACh release was significantly attenuated in mice subjected to either capsaicin injection into the lower hind leg or SNI. These results suggest that α4 nAChRs on GABAergic neurons mediate a cholinergic analgesic circuit in the SNr, and these receptors may be effective therapeutic targets to relieve hyperalgesia in acute and chronic pain, and chronic nicotine exposure.


Subject(s)
GABAergic Neurons , Hyperalgesia , Mice, Inbred C57BL , Receptors, Nicotinic , Animals , Receptors, Nicotinic/metabolism , GABAergic Neurons/metabolism , GABAergic Neurons/drug effects , GABAergic Neurons/physiology , Male , Hyperalgesia/metabolism , Hyperalgesia/drug therapy , Mice , Pars Reticulata/metabolism , Pars Reticulata/drug effects , Nicotine/pharmacology , Analgesics/pharmacology , Nicotinic Agonists/pharmacology , Nicotinic Antagonists/pharmacology , Capsaicin/pharmacology , Acetylcholine/metabolism , Optogenetics , Pain Threshold/drug effects
2.
Acta Pharmacol Sin ; 44(11): 2169-2183, 2023 Nov.
Article in English | MEDLINE | ID: mdl-37322164

ABSTRACT

Excessive self-grooming is an important behavioral phenotype of the stress response in rodents. Elucidating the neural circuit that regulates stress-induced self-grooming may suggest potential treatment to prevent maladaptation to stress that is implicated in emotional disorders. Stimulation of the subthalamic nucleus (STN) has been found to induce strong self-grooming. In this study we investigated the role of the STN and a related neural circuit in mouse stress-related self-grooming. Body-restraint and foot-shock stress-induced self-grooming models were established in mice. We showed that both body restraint and foot shock markedly increased the expression of c-Fos in neurons in the STN and lateral parabrachial nucleus (LPB). Consistent with this, the activity of STN neurons and LPB glutamatergic (Glu) neurons, as assessed with fiber photometry recording, was dramatically elevated during self-grooming in the stressed mice. Using whole-cell patch-clamp recordings in parasagittal brain slices, we identified a monosynaptic projection from STN neurons to LPB Glu neurons that regulates stress-induced self-grooming in mice. Enhanced self-grooming induced by optogenetic activation of the STN-LPB Glu pathway was attenuated by treatment with fluoxetine (18 mg·kg-1·d-1, p.o., for 2 weeks) or in the presence of a cage mate. Furthermore, optogenetic inhibition of the STN-LPB pathway attenuated stress-related but not natural self-grooming. Taken together, these results suggest that the STN-LPB pathway regulates the acute stress response and is a potential target for intervention in stress-related emotional disorders.


Subject(s)
Subthalamic Nucleus , Mice , Animals , Grooming , Subthalamic Nucleus/physiology , Neurons/physiology
3.
Acta Pharmacol Sin ; 43(8): 1928-1939, 2022 Aug.
Article in English | MEDLINE | ID: mdl-34880404

ABSTRACT

The subthalamic nucleus (STN) is one of the best targets for therapeutic deep brain stimulation (DBS) to control motor symptoms in Parkinson's disease. However, the precise circuitry underlying the effects of STN-DBS remains unclear. To understand how electrical stimulation affects STN projection neurons, we used a retrograde viral vector (AAV-retro-hSyn-eGFP) to label STN neurons projecting to the substantia nigra pars reticulata (SNr) (STN-SNr neurons) or the globus pallidus interna (GPi) (STN-GPi neurons) in mice, and performed whole-cell patch-clamp recordings from these projection neurons in ex vivo brain slices. We found that STN-SNr neurons exhibited stronger responses to depolarizing stimulation than STN-GPi neurons. In most STN-SNr and STN-GPi neurons, inhibitory synaptic inputs predominated over excitatory inputs and electrical stimulation at 20-130 Hz inhibited these neurons in the short term; its longer-term effects varied. 6-OHDA lesion of the nigrostriatal dopaminergic pathway significantly reduced inhibitory synaptic inputs in STN-GPi neurons, but did not change synaptic inputs in STN-SNr neurons; it enhanced short-term electrical-stimulation-induced inhibition in STN-SNr neurons but reversed the effect of short-term electrical stimulation on the firing rate in STN-GPi neurons from inhibitory to excitatory; in both STN-SNr and STN-GPi neurons, it increased the inhibition but attenuated the enhancement of firing rate induced by long-term electrical stimulation. Our results suggest that STN-SNr and STN-GPi neurons differ in their synaptic inputs, their responses to electrical stimulation, and their modification under parkinsonian conditions; STN-GPi neurons may play important roles in both the pathophysiology and therapeutic treatment of Parkinson's disease.


Subject(s)
Deep Brain Stimulation , Parkinson Disease , Parkinsonian Disorders , Subthalamic Nucleus , Animals , Deep Brain Stimulation/methods , Electric Stimulation/methods , Mice , Neurons , Parkinson Disease/pathology , Parkinsonian Disorders/therapy , Substantia Nigra/pathology , Substantia Nigra/physiology , Subthalamic Nucleus/pathology , Subthalamic Nucleus/physiology
4.
Acta Pharmacol Sin ; 43(4): 862-875, 2022 Apr.
Article in English | MEDLINE | ID: mdl-34244603

ABSTRACT

The nigrostriatal dopaminergic (DA) system, which includes DA neurons in the ventral and dorsal tiers of the substantia nigra pars compacta (vSNc, dSNc) and DA terminals in the dorsal striatum, is critically implicated in motor control. Accumulating studies demonstrate that both the nigrostriatal DA system and motor function are impaired in aged subjects. However, it is unknown whether dSNc and vSNc DA neurons and striatal DA terminals age in similar patterns, and whether these changes parallel motor deficits. To address this, we performed ex vivo patch-clamp recordings in dSNc and vSNc DA neurons, measured striatal dopamine release, and analyzed motor behaviors in rodents. Spontaneous firing in dSNc and vSNc DA neurons and depolarization-evoked firing in dSNc DA neurons showed inverse V-shaped changes with age. But depolarization-evoked firing in vSNc DA neurons increased with age. In the dorsal striatum, dopamine release declined with age. In locomotor tests, 12-month-old rodents showed hyperactive exploration, relative to 6- and 24-month-old rodents. Additionally, aged rodents showed significant deficits in coordination. Elevating dopamine levels with a dopamine transporter inhibitor improved both locomotion and coordination. Therefore, key components in the nigrostriatal DA system exhibit distinct aging patterns and may contribute to age-related alterations in locomotion and coordination.


Subject(s)
Dopamine , Dopaminergic Neurons , Corpus Striatum , Humans , Pars Compacta , Phenotype , Substantia Nigra/physiology
5.
Acta Pharmacol Sin ; 42(2): 189-198, 2021 Feb.
Article in English | MEDLINE | ID: mdl-32694753

ABSTRACT

Chronic pain is a common and undertreated nonmotor symptom in Parkinson's disease (PD). Although chronic pain is improved by L-dopa in some PD patients, the underlying mechanisms remain unclear. In this study, we established PD mice by unilateral microinjection of 6-OHDA in the medial forebrain bundle to investigate the contribution of spinal cord dopamine receptors to parkinsonian pain hypersensitivity. The von Frey filament tests and thermal pain tests revealed that these PD mice displayed decreased nociceptive thresholds in both hindpaws; intrathecal injection of L-dopa or apomorphine significantly increased the mechanical and thermal nociceptive thresholds, and the analgesic effect was mimicked by ropinirole (a D2 receptor agonist), but not SKF38393 (a D1/D5 receptor agonist), and blocked by sulpiride (a D2 receptor antagonist), but not SKF83566 (a D1/D5 receptor antagonist). Whole-cell recordings in lumber spinal cord slices showed that superficial dorsal horn (SDH) neurons in PD mice exhibited hyperexcitability, including more depolarized resting membrane potentials and more action potentials evoked by depolarizing current steps, which were mitigated by ropinirole. Furthermore, ropinirole inhibited the frequency of spontaneous excitatory postsynaptic currents (sEPSCs) in SDH neurons more strongly in PD mice than in control mice. However, sulpiride caused less disinhibition of sEPSCs in PD mice than in control mice. Taken together, our data reveal that pain hypersensitivity in PD mice is associated with hyperexcitability of SDH neurons, and both events are reversed by activation of spinal D2 receptors. Therefore, spinal D2 receptors can be promising therapeutic targets for the treatment of PD pain.


Subject(s)
Chronic Pain/drug therapy , Parkinsonian Disorders/drug therapy , Posterior Horn Cells/drug effects , Receptors, Dopamine D2/drug effects , Action Potentials/drug effects , Animals , Chronic Pain/etiology , Chronic Pain/physiopathology , Dopamine Agonists/pharmacology , Dopamine Antagonists/pharmacology , Indoles/pharmacology , Male , Mice , Mice, Inbred C57BL , Oxidopamine , Parkinsonian Disorders/complications , Parkinsonian Disorders/physiopathology , Patch-Clamp Techniques , Posterior Horn Cells/metabolism , Receptors, Dopamine D2/metabolism , Spinal Cord/drug effects , Sulpiride/pharmacology
6.
Acta Pharmacol Sin ; 41(1): 1-9, 2020 Jan.
Article in English | MEDLINE | ID: mdl-31554960

ABSTRACT

Midbrain dopaminergic (DA) neurons are governed by an endogenous cholinergic system, originated in the mesopontine nuclei. Nicotine hijacks nicotinic acetylcholine receptors (nAChRs) and interferes with physiological function of the cholinergic system. In this review, we describe the anatomical organization of the cholinergic system and the key nAChR subtypes mediating cholinergic regulation of DA transmission and nicotine reward and dependence, in an effort to identify potential targets for smoking intervention. Cholinergic modulation of midbrain DA systems relies on topographic organization of mesopontine cholinergic projections, and activation of nAChRs in midbrain DA neurons. Previous studies have revealed that α4, α6, and ß2 subunit-containing nAChRs expressed in midbrain DA neurons and their terminals in the striatum regulate firings of midbrain DA neurons and activity-dependent dopamine release in the striatum. These nAChRs undergo modification upon chronic nicotine exposure. Clinical investigation has demonstrated that partial agonists of these receptors elevate the success rate of smoking cessation relative to placebo. However, further investigations are required to refine the drug targets to mitigate unpleasant side-effects.


Subject(s)
Cholinergic Neurons/drug effects , Dopaminergic Neurons/drug effects , Mesencephalon/cytology , Neural Pathways/drug effects , Nicotine/pharmacology , Receptors, Nicotinic/metabolism , Tobacco Use Disorder/metabolism , Animals , Cholinergic Neurons/metabolism , Dopaminergic Neurons/metabolism , Humans , Mesencephalon/drug effects , Mesencephalon/metabolism , Neural Pathways/metabolism
7.
J Biol Chem ; 291(25): 13335-48, 2016 Jun 17.
Article in English | MEDLINE | ID: mdl-27129212

ABSTRACT

Peripheral nerve injury induces increased expression of thrombospondin-4 (TSP4) in spinal cord and dorsal root ganglia that contributes to neuropathic pain states through unknown mechanisms. Here, we test the hypothesis that TSP4 activates its receptor, the voltage-gated calcium channel Cavα2δ1 subunit (Cavα2δ1), on sensory afferent terminals in dorsal spinal cord to promote excitatory synaptogenesis and central sensitization that contribute to neuropathic pain states. We show that there is a direct molecular interaction between TSP4 and Cavα2δ1 in the spinal cord in vivo and that TSP4/Cavα2δ1-dependent processes lead to increased behavioral sensitivities to stimuli. In dorsal spinal cord, TSP4/Cavα2δ1-dependent processes lead to increased frequency of miniature and amplitude of evoked excitatory post-synaptic currents in second-order neurons as well as increased VGlut2- and PSD95-positive puncta, indicative of increased excitatory synapses. Blockade of TSP4/Cavα2δ1-dependent processes with Cavα2δ1 ligand gabapentin or genetic Cavα2δ1 knockdown blocks TSP4 induced nociception and its pathological correlates. Conversely, TSP4 antibodies or genetic ablation blocks nociception and changes in synaptic transmission in mice overexpressing Cavα2δ1 Importantly, TSP4/Cavα2δ1-dependent processes also lead to similar behavioral and pathological changes in a neuropathic pain model of peripheral nerve injury. Thus, a TSP4/Cavα2δ1-dependent pathway activated by TSP4 or peripheral nerve injury promotes exaggerated presynaptic excitatory input and evoked sensory neuron hyperexcitability and excitatory synaptogenesis, which together lead to central sensitization and pain state development.


Subject(s)
Calcium Channels/metabolism , Neuralgia/metabolism , Thrombospondins/physiology , Animals , HEK293 Cells , Humans , Male , Mice, Transgenic , Posterior Horn Cells/physiology , Synapses/physiology , Synaptic Potentials
8.
J Neurosci ; 32(26): 8977-87, 2012 Jun 27.
Article in English | MEDLINE | ID: mdl-22745497

ABSTRACT

Neuropathic pain is a common cause of pain after nerve injury, but its molecular basis is poorly understood. In a post-gene chip microarray effort to identify new target genes contributing to neuropathic pain development, we report here the characterization of a novel neuropathic pain contributor, thrombospondin-4 (TSP4), using a neuropathic pain model of spinal nerve ligation injury. TSP4 is mainly expressed in astrocytes and significantly upregulated in the injury side of dorsal spinal cord that correlates with the development of neuropathic pain states. TSP4 blockade by intrathecal antibodies, antisense oligodeoxynucleotides, or inactivation of the TSP4 gene reverses or prevents behavioral hypersensitivities. Intrathecal injection of TSP4 protein into naive rats is sufficient to enhance the frequency of EPSCs in spinal dorsal horn neurons, suggesting an increased excitatory presynaptic input, and to cause similar behavioral hypersensitivities. Together, these findings support that injury-induced spinal TSP4 may contribute to spinal presynaptic hypersensitivity and neuropathic pain states. Development of TSP4 antagonists has the therapeutic potential for target-specific neuropathic pain management.


Subject(s)
Neuralgia/metabolism , Pain Threshold/physiology , Spinal Cord/metabolism , Thrombospondins/metabolism , Up-Regulation/physiology , 6-Cyano-7-nitroquinoxaline-2,3-dione , Analysis of Variance , Animals , Antibodies/therapeutic use , Disease Models, Animal , Excitatory Amino Acid Antagonists/pharmacology , Green Fluorescent Proteins/genetics , Humans , Hyperalgesia/metabolism , Hyperalgesia/pathology , In Vitro Techniques , Inhibitory Postsynaptic Potentials/drug effects , Inhibitory Postsynaptic Potentials/genetics , Injections, Spinal , Male , Mice , Mice, Transgenic , Motor Activity/drug effects , Neuralgia/drug therapy , Neuralgia/etiology , Oligodeoxyribonucleotides, Antisense/administration & dosage , Pain Measurement , Pain Threshold/drug effects , Rats , Rats, Sprague-Dawley , Sodium Channel Blockers/pharmacology , Spinal Cord/drug effects , Spinal Cord/pathology , Spinal Cord/physiopathology , Spinal Nerves/injuries , Tetrodotoxin/pharmacology , Thrombospondins/deficiency , Thrombospondins/genetics , Up-Regulation/drug effects , Valine/analogs & derivatives , Valine/pharmacology
9.
Acta Pharmacol Sin ; 30(6): 851-8, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19498424

ABSTRACT

AIM: Dopaminergic neurons in the substantia nigra pars compacta (SNc) play important roles in motor control and drug addiction. As the major afferent, GABAergic innervation controls the activity of SNc dopaminergic neurons. Although it is clear that nicotine modulates SNc dopaminergic neurons by activating subtypes of somatodendritic nicotinic acetylcholine receptors (nAChRs), the detailed mechanisms of this activation remain to be addressed. METHODS: In the current study, we recorded GABA(A) receptor-mediated spontaneous inhibitory postsynaptic currents (sIPSCs) from dissociated SNc dopaminergic neurons that were obtained using an enzyme-free procedure. These neurons preserved some functional terminals after isolation, including those that release GABA. RESULTS: We found that both extra- and intra-cellular calcium modulates sIPSCs in these neurons. Furthermore, both nicotine and endogenous acetylcholine enhance the frequency of sIPSCs. Moreover, endogenous acetylcholine tonically facilitates sIPSC frequency, primarily by activating the alpha4beta2* nAChRs on the GABAergic terminals. CONCLUSION: Nicotine facilitates GABA release onto SNc dopaminergic neurons mainly via the activation of presynaptic alpha4beta2* nAChRs.


Subject(s)
Dopamine/metabolism , Nicotine/pharmacology , Nicotinic Agonists/pharmacology , Receptors, GABA-A/metabolism , Acetylcholine/metabolism , Animals , Calcium/metabolism , Glutamic Acid/metabolism , In Vitro Techniques , Inhibitory Postsynaptic Potentials/drug effects , Neurons/metabolism , Rats , Receptors, Nicotinic/drug effects , Receptors, Nicotinic/metabolism , Receptors, Presynaptic/drug effects , Receptors, Presynaptic/metabolism , Substantia Nigra/drug effects , Substantia Nigra/metabolism
10.
Brain Res ; 1088(1): 93-100, 2006 May 09.
Article in English | MEDLINE | ID: mdl-16630593

ABSTRACT

Pb2+ is a common pollutant that causes a wide variety of detrimental effects on developing central nervous system, including cognitive deficit. However, the mechanisms of Pb2+ neurotoxicity remain to be elucidated. GABAergic synaptic transmission in hippocampus is implicated in learning and memory. In the present study, we examined the effects of Pb2+ on GABA(A)-receptor-mediated inhibitory postsynaptic currents (IPSCs), recorded on CA1 pyramidal neurons in rat hippocampal slices, using whole-cell patch clamp recording. Pb2+ significantly inhibited the peak amplitude of evoked IPSCs and increased paired pulse ratio. In addition, Pb2+ (2-50 microM) significantly diminished the frequency of spontaneous IPSCs in a concentration-dependent manner with an IC(50) of 7.56 microM, without changing the amplitude of spontaneous IPSCs. However, Pb2+ (10 microM) did not alter the frequency and amplitude of miniature IPSCs. It was indicated that Pb2+ impaired GABAergic synaptic transmission via a presynaptic mechanism, inhibiting action potential-dependent GABA release. Interestingly, the inhibition of spontaneous IPSC frequency induced by 10 microM Pb2+ was significantly attenuated either in the presence of 100 muM Cd2+ or in a low-calcium (0.5 mM) bath. It suggested the involvement of voltage-gated calcium channels (VGCC) in Pb2+'s inhibition of GABA release. This study provided electrophysiological evidence from developing hippocampal slices to support that Pb2+ inhibited action potential-dependent GABA release by inhibiting presynaptic VGCC, which might be a mechanism for Pb2+ -induced cognitive deficit.


Subject(s)
Calcium Channels/physiology , Hippocampus/cytology , Lead/toxicity , Synaptic Transmission/drug effects , gamma-Aminobutyric Acid/metabolism , Animals , Animals, Newborn , Bicuculline/pharmacology , Cadmium/pharmacology , Calcium/pharmacology , Dose-Response Relationship, Drug , GABA Antagonists/pharmacology , In Vitro Techniques , Male , Neural Inhibition/drug effects , Neurons/drug effects , Neurons/physiology , Patch-Clamp Techniques/methods , Presynaptic Terminals/drug effects , Rats , Rats, Wistar , Tetrodotoxin/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL